Endometrial hyperplasia screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(7 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Endometrial hyperplasia}} | {{Endometrial hyperplasia}} | ||
{{CMG}}{{AE}} {{Swathi}} | |||
==Oveview== | |||
Routine [[Screening (medicine)|screening]] for [[endometrial]] [[hyperplasia]] or [[endometrial]] [[carcinoma]] is not recommended. | |||
==Screening== | |||
* [[Women]] receiving unopposed [[Estrogen|estrogens]] should undergo [[endometrial]] [[sampling]] once every 2 [[Year|years]]. <ref name="pmid1893367">{{cite journal |vauthors=Hakala T, Mecklin JP, Forss M, Järvinen H, Lehtovirta P |title=Endometrial carcinoma in the cancer family syndrome |journal=Cancer |volume=68 |issue=7 |pages=1656–9 |date=October 1991 |pmid=1893367 |doi= |url=}}</ref> | |||
* Particularly if [[endometrial]] hyperstimulation was documented previously and is not been treated by short-term [[progestins]]. | |||
* If high-risk individual requests an [[endometrial]] evaluation before or during [[HRT]]. | |||
* [[Women]] at high risk for [[Endometrial cancer|endometrial carcinoma]], such as history of [[Lynch II syndrome]]. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Line 9: | Line 18: | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Gynecology]] | [[Category:Gynecology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gynecology]] | |||
[[Category:Surgery]] |
Latest revision as of 13:12, 8 May 2019
Endometrial hyperplasia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Endometrial hyperplasia screening On the Web |
American Roentgen Ray Society Images of Endometrial hyperplasia screening |
Risk calculators and risk factors for Endometrial hyperplasia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Swathi Venkatesan, M.B.B.S.[2]
Oveview
Routine screening for endometrial hyperplasia or endometrial carcinoma is not recommended.
Screening
- Women receiving unopposed estrogens should undergo endometrial sampling once every 2 years. [1]
- Particularly if endometrial hyperstimulation was documented previously and is not been treated by short-term progestins.
- If high-risk individual requests an endometrial evaluation before or during HRT.
- Women at high risk for endometrial carcinoma, such as history of Lynch II syndrome.